Consider a group like this one. Dana Whitfield runs eleven locations across the Carolinas, 6.1 million dollars of adjusted EBITDA, and a banker who has told her the window opens in about two years. On paper everything is fine. Then she pulls new patient counts by location and finds that four offices have been flat for nine straight quarters while the two her founding partner practices out of carry a third of group production. She had assumed the flat sites were a staffing issue. The pattern in the data says otherwise: those four offices are simply not being found by the patients already searching in their own ZIP codes. If you have never checked what this looks like in your own practice, you are standing where they stood.
You have run the numbers more than once. Trailing twelve months, adjusted, add-backs listed and ready to defend. The spread between a six and a nine on a group your size is not a rounding error. It is the difference between the outcome you planned for and the one you accept. And almost all of that spread is created before the banker's deck exists. Twelve to twenty four months out, the levers are still live. Ninety days out, they are decoration. The uncomfortable part is that the levers with the most torque are not financial at all. They are structural questions about where your patients come from, whether that source is a system or a habit, and whether any of it would survive your absence.
Why does the 12 to 24 month window decide your multiple?
A buyer underwrites two things: what you earned, and whether it is repeatable. Repeatable takes time to prove. If your patient acquisition changes in month three of a nine month process, you have an anecdote. If it changed twenty months ago and has held every quarter since, you have a trend, and trends are what get capitalised into a multiple.
That lag is the whole argument for starting early. Discovery shifts show up in call volume first, then in new patient counts, then in production, then in collections. Each step adds a quarter. Roughly 432,000 dental searches run through AI assistants every month, and about 70 percent of practices never surface in the results. Your group is almost certainly split across that line right now, some locations visible, some not, and nobody has measured which is which.
That measurement is the cheapest thing you will do this year and the one that most changes what you can honestly claim in a management presentation. Eighteen months gives you time to fix it and time to prove the fix held. Ninety days gives you a slide.
What is an acquirer actually buying when they buy your group?
Not your equipment, not your chairs, not your brand. They are buying cash flow they believe will still be there in year three, under different ownership, with a leadership layer that costs more than you currently pay yourself. Everything in diligence is a test of that belief. The financial review confirms the number. The operational review decides how much of it to trust.
- Transferable demand. Patients who found you through a repeatable channel, not through a relationship that leaves when a person does.
- Predictable acquisition cost. A knowable cost per new patient beats an unknowable one, even when the unknowable one is currently cheaper.
- Concentration risk. One rainmaker location, one referring specialist, one legacy relationship carrying a quarter of production.
- Headroom. Whether a buyer can put capital in and reasonably expect more out.
Dental groups now hold roughly 32 percent of a 179.4 billion dollar market spread across more than 201,000 US practices. Consolidation at that pace means your buyer has already seen dozens of groups this year, and yours gets sorted against them in an afternoon. Understanding how dental practice acquisition teams actually rank what crosses their desk is worth more to you than another add-back.
How much of your EBITDA still walks out the door with you?
This is the question you already know the answer to and would rather not price. Ask it location by location. If your strongest office produces at a level nobody else in the group approaches, find out why before a buyer does. If the reason is a doctor who has been there nineteen years and knows half the town, that production is real and it is also a risk with a name attached.
Owner dependence rarely appears as a line item. It appears as a quality of earnings adjustment, a larger escrow, a longer earn-out, or a multiple that lands a full turn below comparable groups. You experience it as a series of small deductions you cannot argue with, because the underlying observation is correct.
The remedy is not charisma transfer. It is building demand that arrives without a name attached to it. When patients find a location because the location is findable, the production attaches to the office rather than to the person, and a buyer can model it forward without discounting it. Your job in the pre-sale window is to move as much revenue as possible into that column, one office at a time.
Why does referral-dependent growth get discounted in diligence?
Word of mouth is the best possible source of patients and the worst possible source of forecast. A buyer cannot underwrite it because you cannot explain it. Ask most operators where last quarter's new patients came from and the honest answer is a shrug with a good story attached.
That shrug costs you real money. Referral-fed growth is treated as a legacy asset in slow decline and priced at what it produced. Systematic acquisition is treated as an operating capability, and capabilities carry a premium because they can be replicated across the platform after close. Same patients, same revenue, different classification, different price.
Consider where your locations sit on that axis. The offices where new patients arrive through search, through Maps, through an assistant that named you when somebody asked for an implant dentist nearby, those offices have a channel. The offices living on twenty years of goodwill have a history. A demand capture system is what converts the second into the first, and the conversion takes quarters rather than weeks. Which is the entire reason this conversation belongs in year one of the window, not year two.
What does your case mix signal about the next five years?
Buyers read case mix as a forecast. A group producing mostly hygiene and single-unit restorative reads as stable and capped. A group with a genuine elective and surgical base reads as a growth story a buyer can extend with their own capital, which is exactly the story that justifies paying up.
The category rates make the argument for you. Implant cases are growing around 8.5 percent a year at roughly 4,500 dollars average. Cosmetic sits near 6.8 percent at 3,800 dollars. Orthodontics adds 5.1 percent at 5,500 dollars. Your group either participates in those curves or watches them from the sidelines while a buyer prices you accordingly.
Here is what most operators miss. High-value case volume is not primarily a clinical capability problem. It is a discovery problem. Patients researching implants behave nothing like patients booking a cleaning: they search longer, compare more, and increasingly start by asking an assistant who they should see. Patients who arrive that way book high-value treatment at two to three times the rate of general inbound. Absent from that stage, your case mix keeps telling a buyer you are a hygiene business with chairs.
Is your new patient number a system or a coincidence?
Pull the last eight quarters by location. Not the total, the shape. A system produces a line with variance you can explain: seasonality, a staffing gap, a competitor opening two blocks over. A coincidence produces a line that moves for reasons nobody in the room can name.
Buyers study the shape, not the total. They want to know what you did when the number dropped and whether it worked. If the answer is that it recovered on its own, you have described a market rather than a machine, and markets do not come with a premium attached.
- Attribution. You can say, per location, how new patients found you last month. Most groups cannot, and the gap surfaces within five minutes of questioning.
- Repeatability. The same actions produce broadly similar results at the newest location and the oldest one.
- Cost stability. Acquisition cost per patient sits inside a band instead of swinging with whatever was tried that quarter.
- Recovery. When a location dips, there is a known lever rather than a meeting.
Fix the shape and the total tends to follow. Fix the total without the shape and you have simply bought yourself harder questions.
What does a buyer see when they check your locations themselves?
They will check. Somebody on the deal team pulls up your top three offices on a phone in the parking lot before the management presentation. It takes four minutes and it colours everything that comes after.
Here is what that check runs into. About 82 percent of local dental searches end in a Maps interaction, which makes the map result the functional front door for your entire group. A complete, well-maintained business profile earns roughly seven times the clicks of a thin one. If two of your eleven locations have stale hours, no recent photos, and a review response history that stopped in 2023, you are not losing patients hypothetically. You are losing them this week, and your buyer just watched it happen in real time.
What makes this worth addressing early is that it is observable. Unlike culture or clinical quality, visibility can be verified in an afternoon, and improvement across four quarters can be verified too. That is rare in diligence: a claim you can prove rather than assert. Most sellers hand over assertions. Proof is what moves a number, and how a practice signals its value is provable.
A group nobody can find is a group nobody will pay a premium for, no matter how hard you have worked or how much you have spent.
Why do two groups with identical EBITDA sell at different multiples?
Because the number is the starting point, not the conclusion. Two twelve-location groups at 6 million dollars of adjusted EBITDA can be separated by two full turns, and the separation is almost entirely about how those earnings were produced.
| Diligence signal | Positioned group | Unpositioned group | Why it moves the multiple |
|---|---|---|---|
| AI search visibility | Surfaces for local high-intent queries | Among the 70% of practices AI never names | Demand a buyer can extend, or cannot |
| Profile completeness | Complete at every site, roughly 7x click performance | Partial or stale at half the locations | Directly observable inside diligence |
| AI readiness score | Above 65, where only 8% of practices sit | Below the sub-40 national average | Signals durability of new patient flow |
| High-value case mix | Elective share tracking the 8.5% implant curve | Flat, hygiene-weighted production | Forecast growth versus capped growth |
| Acquisition source | Documented channel per location | Referral and legacy goodwill | Operating capability versus legacy asset |
The Dental Index national practice audit · 2026
Read that table as a preview of the questions you will be asked. Every row is something a buyer can check without your cooperation. Your group already sits somewhere on each line, and its position was set by decisions made long before anyone said the word sale. You still have time to move two or three of them.
Which levers actually move the number in eighteen months?
Not all of them, and not the ones that feel most urgent. Sort your options by two questions: can it be measured, and will it season in time to appear in the trailing twelve a buyer prices.
- Visibility parity across locations. Bring your weakest sites up to the standard of your strongest. Only about 8 percent of practices score above 65 on readiness for AI-driven discovery, and the national average sits under 40 out of 100. If your best office is a 70 and your worst is a 22, you are carrying a valuation drag you can retire inside two quarters.
- Case mix shift. Move elective and surgical share upward through who finds you, not through pressure applied at the chair.
- Capacity that holds. With 33.9 percent of practices actively recruiting hygienists, demand you cannot schedule is demand you cannot bank, and a buyer will spot the bottleneck immediately.
- Documentation. Whatever improves, capture the before and after by month and by location while it is happening.
Almost everything else on your list is a year-three project. Run those after close, on someone else's balance sheet.
Earnings quality is a source question, not an accounting question
Operators who defend a premium stopped thinking of EBITDA as a number produced by the P&L and started thinking of it as a number produced by a set of channels. They can trace every dollar back to how a patient found them. That traceability is what a buyer is really paying for, and it is why two identical bottom lines sell for different money.
Visibility is a balance sheet item that never appears on the balance sheet
Groups that close this gap stopped filing discovery under expenses and started filing it under enterprise value. Once you see a location's search position as an asset that compounds into the multiple, the spend decision looks completely different. The ones who never make that shift keep optimising a cost line while the asset quietly erodes.
The best time to build the story is before you need to tell it
Sellers who get the number they wanted were not better negotiators. They simply had two years of evidence when the questions arrived, so nothing in diligence was a surprise and nothing had to be explained away. Everyone else spends the process defending a position instead of presenting one.
Owner dependence is a demand problem wearing a people costume
The groups that solve it stop trying to replace a personality and start making the location findable on its own terms. When patients arrive because the office is visible rather than because someone knows someone, the production stops belonging to a person. That is a structural fix, not a cultural one.
Case mix is downstream of who finds you
Operators who grow elective share understand that it rarely starts at the chair. It starts much earlier, at the moment a patient researching implants decides which three names to consider. Practices absent from that moment end up trying to solve at treatment planning what was already decided during discovery.
What is one invisible location costing you at the closing table?
Run the arithmetic once and it stops being abstract. The audit puts unrealised annual revenue at roughly 147,000 dollars for a typical practice that is not findable where patients are actually looking. That is one location, one year.
Now apply it across your group. Three weak sites is somewhere near 441,000 dollars of revenue that never arrived. Even after the cost to deliver it, the earnings effect is meaningful, and at a seven times multiple, meaningful becomes seven figures of enterprise value. Nobody deducted that from your offer. It simply never entered the trailing twelve your offer was calculated from.
This is the piece operators consistently underweight, because the loss is invisible by definition. There is no line item labelled patients who chose the group two miles away. There is only a production number that looks acceptable because you have never seen it placed next to what the market genuinely supports in those ZIP codes. You can see that comparison. Most sellers never look until a second bidder's diligence report shows it to them, and by then the price has already been anchored.
How do you know whether you are ready to go to market?
Readiness is not a feeling and it is not a data room. It is a short list of claims you can prove on demand.
You should be able to say, without hedging, where new patients came from at every location for the last eight quarters. You should be able to show a visibility position for each site and show that it improved. You should be able to explain your case mix trend and point at what caused it. And you should be able to name the revenue that depends on a specific person, then show what you did to reduce that dependence.
If all four claims are solid, you are negotiating from a position where the multiple is arguable. If two of them are shaky, you are negotiating from a position where every question costs you a fraction of a turn, and those fractions compound quietly across a ninety day process. The gap between those two positions is never built during the process. It is built in the eighteen months when nobody is watching, which is exactly where you are standing right now.
Back to Dana. Those eighteen months did not produce a dramatic quarter. What they produced was a sentence she could say in a management presentation and then defend: here is where every new patient came from, at every location, for two years running. Four offices that had been invisible were visible. Elective share was up. None of it was heroic. It was simply early.
Which is the whole point. Being named by an AI assistant, holding the map pack, showing up when a patient in your ZIP code asks who they should see: none of that sits apart from your valuation. It is the mechanism behind the revenue quality a buyer is pricing. Clear positioning is what makes AI search and Maps ranking work at all, and invisible positioning means an invisible practice regardless of effort or spend. The group two miles away is already being found. You can know exactly where you stand before your buyer tells you.